Atea Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $351.4M |
| Research and development | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M |
| Operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M |
| Pretax income | -$164.5M | -$167.5M | -$134.9M | -$119.5M | $138.6M |
| Income tax expense | -$6.2M | $925,000 | $1.0M | -$3.6M | $17.4M |
| Net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M | $121.2M |
| Balance Sheet | |||||
| Cash and equivalents | $95.7M | $64.7M | $143.8M | $188.5M | $764.4M |
| Current assets | $311.0M | $462.4M | $590.5M | $660.9M | $772.4M |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M |
| Current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
| Stockholders' equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M |
| Depreciation and amortization | $416,000 | $416,000 | $416,000 | $260,000 | $29,000 |
| Stock-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M |
| Capital expenditure | — | — | — | $1.9M | $4,000 |
| Free cash flow | — | — | — | -$122.9M | -$87.0M |
| Share repurchases | $25.5M | $0 | — | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 80.0M · Free float 79.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.